<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00131378</url>
  </required_header>
  <id_info>
    <org_study_id>525</org_study_id>
    <secondary_id>MGH GCRC 678</secondary_id>
    <secondary_id>2004-P-000013</secondary_id>
    <secondary_id>R01HL077674</secondary_id>
    <nct_id>NCT00131378</nct_id>
  </id_info>
  <brief_title>Growth Hormone, Cardiovascular Risk, and Visceral Adiposity</brief_title>
  <official_title>Growth Hormone, Cardiovascular Risk, and Visceral Adiposity</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Massachusetts General Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Massachusetts General Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will compare growth hormone levels and cardiovascular risk markers in normal
      weight and overweight women and men. In women and men with increased abdominal weight, growth
      hormone (GH) versus placebo will be administered and effects on cardiovascular risk, insulin
      resistance and body composition will be measured.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The purpose of this study is to measure growth hormone levels in women and men who are normal
      weight, overweight, and obese. Growth hormone levels will be correlated with body weight,
      body composition, and markers of cardiovascular risk. In overweight or obese women and men
      with increased visceral adiposity and below average IGF-1 levels, growth hormone versus
      placebo will be given for 6 months. Effects of growth hormone treatment on weight, body
      composition, insulin resistance, lipids, and cardiovascular risk markers will then be
      assessed. Study subjects will be followed for an additional six months for these endpoints.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 2004</start_date>
  <completion_date type="Actual">June 2013</completion_date>
  <primary_completion_date type="Actual">November 2012</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>HsCRP</measure>
    <time_frame>Measured at baseline and month 6</time_frame>
    <description>6 month change in HsCRP (primary cardiovascular risk endpoint)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Total Abdominal Fat</measure>
    <time_frame>Measured at baseline and month 6</time_frame>
    <description>6 month change in total abdominal fat (primary body composition endpoint)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Abdominal Fat</measure>
    <time_frame>Measured at baseline and month 6</time_frame>
    <description>6 month change in visceral abdominal fat (primary body composition endpoint)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Measure of Insulin Resistance</measure>
    <time_frame>Measured at baseline and month 6</time_frame>
    <description>6 month change in 2-hour glucose (primary insulin resistance endpoint)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Insulin-like Growth Factor-1 (IGF-1) Levels</measure>
    <time_frame>Measured at baseline and month 6</time_frame>
    <description>6-month change in IGF-1 levels</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">142</enrollment>
  <condition>Obesity</condition>
  <arm_group>
    <arm_group_label>Male on GH</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants received growth hormone replacement therapy. The starting dose was 2 micrograms/kg per day and they were titrated within the normal range based on blood levels.
Nutropin AQ growth hormone : Participants gave themselves injections of growth hormone every night for 6 months.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Male on Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Participants received placebo.
Placebo Growth Hormone : Participants gave themselves injections of placebo every night for 6 months.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Female on GH</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants received growth hormone replacement therapy. The starting dose was 4 micrograms/kg per day and they were titrated within the normal range based on blood levels.
Nutropin AQ growth hormone : Participants gave themselves injections of growth hormone every night for 6 months.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Female on Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Participants received placebo.
Placebo Growth Hormone : Participants gave themselves injections of placebo every night for 6 months.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nutropin AQ growth hormone</intervention_name>
    <description>Participants will give themselves injections of growth hormone every night for 6 months.</description>
    <arm_group_label>Male on GH</arm_group_label>
    <arm_group_label>Female on GH</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo Growth Hormone</intervention_name>
    <description>Participants will give themselves injections of placebo growth hormone every night for 6 months.</description>
    <arm_group_label>Male on Placebo</arm_group_label>
    <arm_group_label>Female on Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  For growth hormone measurement part (for men and women):

               1. For visceral adiposity arm: waist circumference greater than or equal to 88 cm
                  for women or 102 cm for men, and BMI greater than or equal to 25 kg/m2

               2. For lean controls: BMI 18.5 to 24.9 kg/m2

          -  For growth hormone treatment part (for men and women):

               1. Visceral adiposity (waist circumference greater than or equal to 88 cm for women
                  and 102 for men, BMI greater than or equal to 25 kg/m2)

               2. IGF-I within the lowest 2 quartiles for age and gender

               3. Willingness to maintain current activity level and diet

        Exclusion Criteria:

          -  Diabetes mellitus (fasting plasma glucose greater than 126 mg/dL or 2-hour post-oral
             glucose tolerance test [OGTT] plasma glucose greater than 200)

          -  Taking the following medications in the last 3 months: weight loss or lipid-lowering
             agents, medications to treat diabetes mellitus or &quot;pre-diabetes&quot;, oral contraceptives
             or estrogen-containing medications, other medications known to significantly affect
             weight

          -  Smoking

          -  Hematocrit below the lower limit of normal

          -  Amenorrhea for 3 months (in women)

          -  Pregnant or breastfeeding (in women)

          -  Polycystic ovary syndrome (in women)

          -  Weight that exceeds 280 pounds

          -  SGPT greater than 2 times the upper limit of normal

          -  History of malignancy, except for fully resolved basal cell carcinomas of the skin
             (Specific Aim 2 only)

          -  Radiation exposure greater than 1000 mrem over the last 12 months

          -  Previous diagnosis of cardiovascular disease

          -  History of pituitary or hypothalamic disease, brain radiation, or childhood growth
             hormone deficiency

          -  History of carpal tunnel syndrome that has not been surgically treated
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Karen K. Miller, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Massachusetts General Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Massachusetts General Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 16, 2005</study_first_submitted>
  <study_first_submitted_qc>August 16, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 18, 2005</study_first_posted>
  <results_first_submitted>August 19, 2013</results_first_submitted>
  <results_first_submitted_qc>February 4, 2014</results_first_submitted_qc>
  <results_first_posted type="Estimate">March 6, 2014</results_first_posted>
  <last_update_submitted>March 9, 2016</last_update_submitted>
  <last_update_submitted_qc>March 9, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 11, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Massachusetts General Hospital</investigator_affiliation>
    <investigator_full_name>Karen Klahr Miller, MD</investigator_full_name>
    <investigator_title>Associate Professor of Medicine</investigator_title>
  </responsible_party>
  <keyword>Visceral obesity</keyword>
  <keyword>Growth hormone</keyword>
  <keyword>Cardiovascular risk</keyword>
  <keyword>Insulin resistance</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hormones</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Female on GH</title>
          <description>Participants received growth hormone replacement therapy. The starting dose was 4 micrograms/kg per day and they were titrated within the normal range based on blood levels.
Nutropin AQ growth hormone : Participants gave themselves injections of growth hormone every night for 6 months.</description>
        </group>
        <group group_id="P2">
          <title>Female on Placebo</title>
          <description>Participants received placebo.
Placebo Growth Hormone : Participants gave themselves injections of placebo every night for 6 months.</description>
        </group>
        <group group_id="P3">
          <title>Male on GH</title>
          <description>Participants received growth hormone replacement therapy. The starting dose was 2 micrograms/kg per day and they were titrated within the normal range based on blood levels.
Nutropin AQ growth hormone : Participants gave themselves injections of growth hormone every night for 6 months.</description>
        </group>
        <group group_id="P4">
          <title>Male on Placebo</title>
          <description>Participants received placebo.
Placebo Growth Hormone : Participants gave themselves injections of placebo every night for 6 months.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="40"/>
                <participants group_id="P2" count="40"/>
                <participants group_id="P3" count="32"/>
                <participants group_id="P4" count="30"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="29"/>
                <participants group_id="P2" count="22"/>
                <participants group_id="P3" count="22"/>
                <participants group_id="P4" count="21"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="11"/>
                <participants group_id="P2" count="18"/>
                <participants group_id="P3" count="10"/>
                <participants group_id="P4" count="9"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Female on GH</title>
          <description>Participants received growth hormone replacement therapy. The starting dose was 4 micrograms/kg per day and they were titrated within the normal range based on blood levels.
Nutropin AQ growth hormone : Participants gave themselves injections of growth hormone every night for 6 months.</description>
        </group>
        <group group_id="B2">
          <title>Female on Placebo</title>
          <description>Participants received placebo.
Placebo Growth Hormone : Participants gave themselves injections of placebo every night for 6 months.</description>
        </group>
        <group group_id="B3">
          <title>Male on GH</title>
          <description>Participants received growth hormone replacement therapy. The starting dose was 2 micrograms/kg per day and they were titrated within the normal range based on blood levels.
Nutropin AQ growth hormone : Participants gave themselves injections of growth hormone every night for 6 months.</description>
        </group>
        <group group_id="B4">
          <title>Male on Placebo</title>
          <description>Participants received placebo.
Placebo Growth Hormone : Participants gave themselves injections of placebo every night for 6 months.</description>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="40"/>
            <count group_id="B2" value="40"/>
            <count group_id="B3" value="32"/>
            <count group_id="B4" value="30"/>
            <count group_id="B5" value="142"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="40"/>
                    <measurement group_id="B2" value="40"/>
                    <measurement group_id="B3" value="32"/>
                    <measurement group_id="B4" value="30"/>
                    <measurement group_id="B5" value="142"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="35.7" spread="1.1"/>
                    <measurement group_id="B2" value="36.1" spread="1.1"/>
                    <measurement group_id="B3" value="32.4" spread="1.2"/>
                    <measurement group_id="B4" value="34.3" spread="1.1"/>
                    <measurement group_id="B5" value="34.6" spread="1.13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="40"/>
                    <measurement group_id="B2" value="40"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="80"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="32"/>
                    <measurement group_id="B4" value="30"/>
                    <measurement group_id="B5" value="62"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="40"/>
                    <measurement group_id="B2" value="40"/>
                    <measurement group_id="B3" value="32"/>
                    <measurement group_id="B4" value="30"/>
                    <measurement group_id="B5" value="142"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>HsCRP</title>
        <description>6 month change in HsCRP (primary cardiovascular risk endpoint)</description>
        <time_frame>Measured at baseline and month 6</time_frame>
        <population>ITT</population>
        <group_list>
          <group group_id="O1">
            <title>Male on GH</title>
            <description>Participants received growth hormone replacement therapy. The starting dose was 2 micrograms/kg per day and they were titrated within the normal range based on blood levels.
Nutropin AQ growth hormone : Participants gave themselves injections of growth hormone every night for 6 months.</description>
          </group>
          <group group_id="O2">
            <title>Male on Placebo</title>
            <description>Participants received placebo.
Placebo Growth Hormone : Participants gave themselves injections of placebo every night for 6 months.</description>
          </group>
          <group group_id="O3">
            <title>Female on GH</title>
            <description>Participants received growth hormone replacement therapy. The starting dose was 4 micrograms/kg per day and they were titrated within the normal range based on blood levels.
Nutropin AQ growth hormone : Participants gave themselves injections of growth hormone every night for 6 months.</description>
          </group>
          <group group_id="O4">
            <title>Female on Placebo</title>
            <description>Participants received placebo.
Placebo Growth Hormone : Participants gave themselves injections of placebo every night for 6 months.</description>
          </group>
        </group_list>
        <measure>
          <title>HsCRP</title>
          <description>6 month change in HsCRP (primary cardiovascular risk endpoint)</description>
          <population>ITT</population>
          <units>mg/L</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="32"/>
                <count group_id="O2" value="30"/>
                <count group_id="O3" value="40"/>
                <count group_id="O4" value="40"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.1" spread="0.5"/>
                    <measurement group_id="O2" value="0.5" spread="0.3"/>
                    <measurement group_id="O3" value="-1.3" spread="0.2"/>
                    <measurement group_id="O4" value="-0.3" spread="0.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Measure of Insulin Resistance</title>
        <description>6 month change in 2-hour glucose (primary insulin resistance endpoint)</description>
        <time_frame>Measured at baseline and month 6</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Male on GH</title>
            <description>Participants received growth hormone replacement therapy. The starting dose was 2 micrograms/kg per day and they were titrated within the normal range based on blood levels.
Nutropin AQ growth hormone : Participants gave themselves injections of growth hormone every night for 6 months.</description>
          </group>
          <group group_id="O2">
            <title>Male on Placebo</title>
            <description>Participants received placebo.
Placebo Growth Hormone : Participants gave themselves injections of placebo every night for 6 months.</description>
          </group>
          <group group_id="O3">
            <title>Female on GH</title>
            <description>Participants received growth hormone replacement therapy. The starting dose was 4 micrograms/kg per day and they were titrated within the normal range based on blood levels.
Nutropin AQ growth hormone : Participants gave themselves injections of growth hormone every night for 6 months.</description>
          </group>
          <group group_id="O4">
            <title>Female on Placebo</title>
            <description>Participants received placebo.
Placebo Growth Hormone : Participants gave themselves injections of placebo every night for 6 months.</description>
          </group>
        </group_list>
        <measure>
          <title>Measure of Insulin Resistance</title>
          <description>6 month change in 2-hour glucose (primary insulin resistance endpoint)</description>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="32"/>
                <count group_id="O2" value="30"/>
                <count group_id="O3" value="40"/>
                <count group_id="O4" value="40"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.3" spread="5.6"/>
                    <measurement group_id="O2" value="-12.5" spread="5.8"/>
                    <measurement group_id="O3" value="18.6" spread="6.3"/>
                    <measurement group_id="O4" value="-0.9" spread="8.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Insulin-like Growth Factor-1 (IGF-1) Levels</title>
        <description>6-month change in IGF-1 levels</description>
        <time_frame>Measured at baseline and month 6</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Male on GH</title>
            <description>Participants received growth hormone replacement therapy. The starting dose was 2 micrograms/kg per day and they were titrated within the normal range based on blood levels.
Nutropin AQ growth hormone : Participants gave themselves injections of growth hormone every night for 6 months.</description>
          </group>
          <group group_id="O2">
            <title>Male on Placebo</title>
            <description>Participants received placebo.
Placebo Growth Hormone : Participants gave themselves injections of placebo every night for 6 months.</description>
          </group>
          <group group_id="O3">
            <title>Female on GH</title>
            <description>Participants received growth hormone replacement therapy. The starting dose was 4 micrograms/kg per day and they were titrated within the normal range based on blood levels.
Nutropin AQ growth hormone : Participants gave themselves injections of growth hormone every night for 6 months.</description>
          </group>
          <group group_id="O4">
            <title>Female on Placebo</title>
            <description>Participants received placebo.
Placebo Growth Hormone : Participants gave themselves injections of placebo every night for 6 months.</description>
          </group>
        </group_list>
        <measure>
          <title>Insulin-like Growth Factor-1 (IGF-1) Levels</title>
          <description>6-month change in IGF-1 levels</description>
          <units>ng/mL</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="32"/>
                <count group_id="O2" value="30"/>
                <count group_id="O3" value="40"/>
                <count group_id="O4" value="40"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="179.0" spread="31.5"/>
                    <measurement group_id="O2" value="9.9" spread="7.8"/>
                    <measurement group_id="O3" value="106.5" spread="17.5"/>
                    <measurement group_id="O4" value="-20.8" spread="7.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Total Abdominal Fat</title>
        <description>6 month change in total abdominal fat (primary body composition endpoint)</description>
        <time_frame>Measured at baseline and month 6</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Female on GH</title>
            <description>Participants received growth hormone replacement therapy. The starting dose was 4 micrograms/kg per day and they were titrated within the normal range based on blood levels.
Nutropin AQ growth hormone : Participants gave themselves injections of growth hormone every night for 6 months.</description>
          </group>
          <group group_id="O2">
            <title>Female on Placebo</title>
            <description>Participants received placebo.
Placebo Growth Hormone : Participants gave themselves injections of placebo every night for 6 months.</description>
          </group>
        </group_list>
        <measure>
          <title>Total Abdominal Fat</title>
          <description>6 month change in total abdominal fat (primary body composition endpoint)</description>
          <units>cm^2</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="40"/>
                <count group_id="O2" value="40"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-28.0" spread="9.7"/>
                    <measurement group_id="O2" value="1.5" spread="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Abdominal Fat</title>
        <description>6 month change in visceral abdominal fat (primary body composition endpoint)</description>
        <time_frame>Measured at baseline and month 6</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Male on GH</title>
            <description>Participants received growth hormone replacement therapy. The starting dose was 2 micrograms/kg per day and they were titrated within the normal range based on blood levels.
Nutropin AQ growth hormone : Participants gave themselves injections of growth hormone every night for 6 months.</description>
          </group>
          <group group_id="O2">
            <title>Male on Placebo</title>
            <description>Participants received placebo.
Placebo Growth Hormone : Participants gave themselves injections of placebo every night for 6 months.</description>
          </group>
        </group_list>
        <measure>
          <title>Abdominal Fat</title>
          <description>6 month change in visceral abdominal fat (primary body composition endpoint)</description>
          <units>cm^2</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="32"/>
                <count group_id="O2" value="30"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-15.9" spread="6.3"/>
                    <measurement group_id="O2" value="-0.2" spread="7.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Female on GH</title>
          <description>Participants received growth hormone replacement therapy. The starting dose was 4 micrograms/kg per day and they were titrated within the normal range based on blood levels.
Nutropin AQ growth hormone : Participants gave themselves injections of growth hormone every night for 6 months.</description>
        </group>
        <group group_id="E2">
          <title>Female on Placebo</title>
          <description>Participants received placebo.
Placebo Growth Hormone : Participants gave themselves injections of placebo every night for 6 months.</description>
        </group>
        <group group_id="E3">
          <title>Male on GH</title>
          <description>Participants received growth hormone replacement therapy. The starting dose was 2 micrograms/kg per day and they were titrated within the normal range based on blood levels.
Nutropin AQ growth hormone : Participants gave themselves injections of growth hormone every night for 6 months.</description>
        </group>
        <group group_id="E4">
          <title>Male on Placebo</title>
          <description>Participants received placebo.
Placebo Growth Hormone : Participants gave themselves injections of placebo every night for 6 months.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Breast Cancer</sub_title>
                <description>Development of breast cancer in a subject on placebo.</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>MVA - motor vehicle accident</sub_title>
                <description>Motor vehicle accident in a male subject on placebo.</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>2</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="40"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="32"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>New onset atrial fibrillation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Abnormal Glucose Measurements</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="40"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="32"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Goiter</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Breast Calcification on Mammogram</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Carpel Tunnel Symptoms</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="32"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Cervical HPV</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Breast Lump</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Karen K. Miller</name_or_title>
      <organization>Massachusetts General Hospital</organization>
      <phone>617-726-3870</phone>
      <email>kkmiller@partners.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

